Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus

Inclusion Criteria: * Patients who has been receiving a stable dose and regimen of GLP-1 analogue over 12 weeks before administration of investigational dug * Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug * Patients with HbA1c of ≥7.0% and \<10.5% * Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug Exclusion Criteria: * Patients with type 1 diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (Cushing's syndrome, acromegaly, etc.) * Patients with severe diabetic complications (proliferative diabetic retinopathy, stage 4 nephropathy, or serious diabetic neuropathy) * Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria * Patients with systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg * Patients with serious renal or hepatic disease * Patients with eGFR of \<45 mL/min/1.73 m2 * Patients who are the excessive alcohol addicts * Patients requiring insulin therapy * Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception